Short Interest in Sensus Healthcare, Inc. (NASDAQ:SRTS) Drops By 18.3%

Sensus Healthcare, Inc. (NASDAQ:SRTS) was the target of a significant drop in short interest in March. As of March 13th, there was short interest totaling 394,950 shares, a drop of 18.3% from the February 26th total of 483,655 shares. Based on an average trading volume of 102,973 shares, the short-interest ratio is presently 3.8 days. Currently, 2.6% of the company’s stock are short sold.

Sensus Healthcare Stock Up 2.8%

Shares of NASDAQ:SRTS opened at $3.98 on Wednesday. The business has a 50 day moving average price of $4.36 and a 200 day moving average price of $3.99. Sensus Healthcare has a twelve month low of $3.03 and a twelve month high of $5.92. The company has a market cap of $65.51 million, a price-to-earnings ratio of -8.47 and a beta of 1.22.

Sensus Healthcare (NASDAQ:SRTS) last issued its quarterly earnings results on Thursday, February 12th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.10). Sensus Healthcare had a negative return on equity of 15.11% and a negative net margin of 28.09%.The business had revenue of $4.94 million during the quarter, compared to the consensus estimate of $8.35 million. Analysts anticipate that Sensus Healthcare will post 0.32 EPS for the current year.

Analyst Upgrades and Downgrades

SRTS has been the topic of a number of research reports. Wall Street Zen downgraded Sensus Healthcare from a “hold” rating to a “sell” rating in a report on Saturday, February 14th. Maxim Group decreased their target price on Sensus Healthcare from $8.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, February 17th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Sensus Healthcare in a report on Thursday, January 22nd. Finally, Alliance Global Partners began coverage on shares of Sensus Healthcare in a research note on Friday, March 6th. They issued a “buy” rating and a $7.50 target price on the stock. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $6.88.

Hedge Funds Weigh In On Sensus Healthcare

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Pacific Ridge Capital Partners LLC raised its stake in Sensus Healthcare by 21.8% during the 4th quarter. Pacific Ridge Capital Partners LLC now owns 698,634 shares of the company’s stock valued at $2,781,000 after purchasing an additional 125,245 shares during the last quarter. Divisadero Street Capital Management LP increased its holdings in shares of Sensus Healthcare by 39.5% during the 3rd quarter. Divisadero Street Capital Management LP now owns 452,897 shares of the company’s stock worth $1,422,000 after purchasing an additional 128,224 shares during the period. Geode Capital Management LLC raised its position in shares of Sensus Healthcare by 3.5% during the fourth quarter. Geode Capital Management LLC now owns 158,240 shares of the company’s stock valued at $630,000 after buying an additional 5,316 shares during the last quarter. Sachetta LLC raised its position in shares of Sensus Healthcare by 6.8% during the fourth quarter. Sachetta LLC now owns 148,508 shares of the company’s stock valued at $591,000 after buying an additional 9,500 shares during the last quarter. Finally, Greenline Wealth Management LLC bought a new stake in shares of Sensus Healthcare in the fourth quarter valued at about $513,000. Institutional investors own 25.30% of the company’s stock.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.